Trial
NCT03220347
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90010 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin's Lymphomas
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Celgene
Collaborators
—
Condition
Lymphoma, Non-Hodgkin
Intervention
CC-90010
Why stopped
Business objectives have changed
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-10-08